{"url_path":"/sec/srpt/8-k/2026-06-04/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/873303/0001193125-26-257501-index.html","accession_number":"0001193125-26-257501","cik":"0000873303","ticker":"SRPT","issuer_name":"Sarepta Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/873303/0001193125-26-257501-index.html","primary_entity_key":"0000873303","primary_entity_name":"Sarepta Therapeutics, Inc."},"word_count":355,"has_tables":true,"body_markdown":"Item 5.07. Submission of Matters to a Vote of Security Holders.\n\nThe following is a brief description of each proposal voted upon at the Annual Meeting and the final voting results for each such proposal. As of the record date for the Annual Meeting, April 8, 2026, there were 105,571,146 shares of common stock outstanding and entitled to vote at the Annual Meeting. There were 82,309,288 shares of common stock entitled to vote at the Annual Meeting present online or represented by proxy, which represented 77.97% of the outstanding shares entitled to vote at the Annual Meeting, and which constituted a quorum for the transaction of business.\n\nProposal 1: Election of Directors\n\nThe director nominees listed below were elected to serve on the Company’s board of directors as members of Class I for a term of two years. The results of the vote were as follows:\n\n \n\nName of Nominee\n\n  \n  For  \n  \n  Against  \n  \n  Abstain  \n  \n\nBroker Non-Votes\n\nDouglas S. Ingram\n  \n66,812,593\n  \n827,973\n  \n52,441\n  \n\n14,616,281\n\nHans Wigzell, M.D., Ph.D.\n  \n56,984,756\n  \n10,663,180\n  \n45,071\n  \n\n14,616,281\n\nKathryn J. Boor, Ph.D.\n  \n63,915,239\n  \n3,722,626\n  \n55,142\n  \n\n14,616,281\n\nMichael Chambers\n  \n65,892,431\n  \n1,752,077\n  \n48,499\n  \n\n14,616,281\n\nDeirdre Connelly\n  \n53,419,881\n  \n14,213,242\n  \n59,884\n  \n\n14,616,281\n\nProposal 2: Advisory Vote to Approve Named Executive Officer Compensation\n\nThe stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers for 2025. The results of the advisory vote were as follows:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n45,185,398\n\n \n\n22,373,065\n\n \n\n134,544\n\n \n\n14,616,281\n\nProposal 3: Approval of the Company ’s 2026 Equity Incentive Plan\n\nThe stockholders approved the 2026 Plan. The results of the vote were as follows:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n63,233,193\n\n \n\n4,395,283\n\n \n\n64,531\n\n \n\n14,616,281\n\nProposal 4: Approval of the Company ’s 2026 Employee Stock Purchase Plan\n\nThe stockholders approved the 2026 ESPP. The results of the vote were as follows:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n67,098,699\n\n \n\n532,525\n\n \n\n61,783\n\n \n\n14,616,281\n\nProposal 5: Ratification of KPMG as the Company ’s Independent Registered Public Accounting Firm\n\nThe stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2026. The results of the vote were as follows:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n79,907,368\n\n \n\n2,110,136\n\n \n\n291,784"}